Aclaris Therapeautics Reports Positive Phase 2 Clinical Trial Results
On June 28, Aclaris Therapeutics (ACRS) reported positive interim results from its Phase 2 clinical trial of AA-202 Topical. The drug is an investigational topical to treat two of the more severe variants of Alopecia Areata. Patients did not experience any treatment-related serious adverse events, and results for the full patient sample will be reported in the future.
Sonal sent an alert to subscribers at 4:30 pm. The next trade took place at 4:42 pm for $19.16. The stock opened the next morning for regular market trading at $19.19. The stock price continued to move higher throughout the day before closing at $19.97 for a gain of 4.2% on the event day.
Aclaris Therapeutics’ stock price continued to move higher over the next five trading sessions. The stock closed at $20.80 on July 9 for a gain of 5.4% following the news event.
If you want to learn more about trading on clinical trial results, visit the Knowledge Center.
To see the latest weekly webinar, you can visit our Live Webinar page.
Subscribe here if you would like to start receiving these signals in real-time and start trading!